ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients

A. Lichvar,1 S. Tremblay,2 D. Naik,2 E. King,4 A. Vinks,4 U. Christians,3 J. Lipscomb,4 R. Alloway.2

1U of Illinois at Chicago, Chicago, IL
2U of Cincinnati, Cincinnati, OH
3U of Colorado, Denver, CO
4Cincinnati Children's, Cincinnati, OH.

Meeting: 2018 American Transplant Congress

Abstract number: C291

Keywords: High-risk, Immunosuppression, Pharmacokinetics, Renal function

Session Information

Session Name: Poster Session C: Psychosocial and Treatment Adherence

Session Type: Poster Session

Date: Monday, June 4, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Background: Long-term studies with control groups are required to assess tacrolimus (TAC) conversion. The purpose of this study was to compare clinical and safety outcomes of transplant (txp) recipients converted between different TAC products to those who were maintained on a single TAC formulation.

Methods: A retrospective, single-center study of txp recipients with pharmacy refill data was conducted from 08/09-05/16. Four groups were assessed: Group A) brand TAC, B) generic TAC (Sandoz), C) single conversion from brand name to generic, D) multiple conversions. Index date was either the date of first TAC product conversion (Groups C and D) or a pre-specified post-txp time (Groups A and B), selected by assessing the time to conversion post-txp in the intervention groups. Linear trend was estimated for dose-normalized TAC levels and eGFR using regression models allowing for differing slopes for each period (pre- vs post-index date) and across groups.

Results: 100 patients were included (A=29, B=19, C=26, D=26). Table 1 lists demographics. After the index date, 43% of patients had TAC dose modification and dose changes were similar across the groups (Table 2 and 3). No differences in hospitalization or rejection (Table 4). Linear trends in dose-normalized TAC levels across all 4 groups were similar (pre-index date period p=0.52; post-index date period p=0.08) (Figure 1) and in eGFR were similar (pre-index date p=0.65; post-index date period p=0.17) (Figure 2). P-values in Figures 1 and 2 represent pre- vs post index date by group. Group B had significantly lower troughs post-index date.

Conclusion: No significant differences were observed between any groups regarding dose modification, dose-normalized TAC trough concentrations, or other notable adverse drug effects. Significant dose-normalized TAC variability was observed in Group B pre-and post-index date periods, despite remaining on the same generic product.

CITATION INFORMATION: Lichvar A., Tremblay S., Naik D., King E., Vinks A., Christians U., Lipscomb J., Alloway R. Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Lichvar A, Tremblay S, Naik D, King E, Vinks A, Christians U, Lipscomb J, Alloway R. Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients [abstract]. https://atcmeetingabstracts.com/abstract/evaluation-of-clinical-and-safety-outcomes-following-uncontrolled-tacrolimus-conversion-in-adult-transplant-recipients/. Accessed June 4, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences